Company
Verici Dx PLC
LON:VRCI
Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. Its products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
12 stories
Archive
Small Cap Wrap - Angling Direct, Ascent Resources, Deltic Energy and more...
The natural resources investing company with a high impact, natural gas focussed exploration and appraisal portfolio in the Southern North Sea, announced completion of the farm-out agreement of five of its gas licences in the Southern North
Verici Dx makes bright start as trading begins on AIM
Verici Dx specialises in immune phenotyping or tests that can evaluate how well a patient will react to a transplant